Product information
From Health Canada
The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.
Current status:
Approved
Current status date:
2021-10-14
Product name:
NOREPINEPHRINE BITARTRATE INJECTION
DIN:
02521385
Product Monograph/Veterinary Labelling:
Date:
2021-10-13
Product monograph/Veterinary Labelling (PDF version ~ 175K)
Company:
ACALA PHARMACEUTICALS INC. (A DIVISION OF FERNBANK MANAGEMENT CORPORATION)
1702
224 King St W
Toronto
Ontario
Canada
M5H 0A6
Class:
Human
Dosage form(s):
Solution
Route(s) of administration:
Intravenous
Number of active ingredient(s):
1
Schedule(s):
Ethical
American Hospital Formulary Service (AHFS): See footnote 3
12:12.12
Anatomical Therapeutic Chemical (ATC): See footnote 4
C01CA03 NOREPINEPHRINE
Active ingredient group (AIG) number:See footnote5
0131301001
| Active ingredient(s) | Strength |
|---|---|
| NOREPINEPHRINE (NOREPINEPHRINE BITARTRATE MONOHYDRATE) | 1 MG / ML |